2-propylethoxybenzene | 101144-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-propylethoxybenzene
• 英文别名: 1-n-Propyl-2-ethoxybenzol；2-propyl-phenetole；2-Propyl-phenetol；1-ethoxy-2-propyl-benzene；ethoxy-2-propylbenzene；1-ethoxy-2-propylbenzene
• CAS: 101144-90-5
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: JOKQVDKUGLMFLU-UHFFFAOYSA-N

物化性质

• 沸点：
  213°C (estimate)
• 密度：
  0.9240

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  丁二酸酐 、 2-propylethoxybenzene 在 aluminum (III) chloride 、 盐酸 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 4-(4-ethoxy-3-propylphenyl)-4-oxobutanoic acid
  参考文献：
  名称：

  WO2006/82952

  摘要：

  公开号：
• 作为产物：
  描述：

  2-乙氧基苯甲醛 在 乙醇 、 sodium proprionate 、 sodium 作用下， 生成 2-propylethoxybenzene
  参考文献：
  名称：

  Antifungal Pharmacodynamic Characteristics of Amphotericin B againstTrichosporon asahii, Using Time-Kill Methodology

  摘要：

  AbstractWe determined the MIC of amphotericin B against 45 Trichosporon asahii isolates from various clinical and environmental sources, and used in vitro time‐kill methods to characterize the relationship between amphotericin B concentrations and MIC for four representative T. asahii isolates. Amphotericin B had concentration‐dependent antifungal activity. MICs ranged from 0.5 to 16 μg/ml, and most T. asahii isolates (76%, 34/45) were inhibited at safely achievable amphotericin B serum concentrations (≤ 2 μg/ml). However, 40% (18/45) of isolates were not killed at these concentrations (MFCs from 1.0 to 32 μg/ml). At concentrations ≥ 2 × MIC, amphotericin B exhibited fungicidal activity (< 99.9% reduction in CFU) over a 12‐hr time‐period; the maximal effect was achieved at ≥ 4 × MIC. Susceptibility testing confirmed the resistance of T. asahii to amphotericin B, and in vitro pharmacodynamic results also suggest that amphotericin B is not suitable therapy for T. asahii infection.

  DOI：

  10.1111/j.1348-0421.2002.tb02663.x

文献信息

• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Blaney Jeffrey

  公开号：US20120022043A1

  公开（公告）日：2012-01-26

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

  该发明提供了Formula Ia的JAK激酶抑制剂，其对映体、二对映体或其药学上可接受的盐，其中R1、R2、R7和Z在此处定义，包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
• GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF
  申请人：HEYMAN Norman S.

  公开号：US20130029924A1

  公开（公告）日：2013-01-31

  Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.

  提供了糖基化的丙戊酸及其类似物。在某些实施方式中，糖基化的丙戊酸及其类似物具有改善的溶解性，并且非常适合用于药物输送以治疗各种疾病。
• Base Mediated Aromatization of Carbonyl Condensation Products Derived from 2‐(2‐Bromoprop‐2‐enyl)cyclohexanone Derivatives<i>via</i>‘<i>Intramolecular Unsaturation Transfer</i>’
  作者：Emre Y. Yazıcıoğlu、İdris M. Akhmedov、Cihangir Tanyeli

  DOI：10.1002/hlca.200890124

  日期：2008.6

  2-propargylcyclohexanone with alcohols, amines, or amino alcohols, followed by base treatment (Scheme 1). Phenolic ethers and N-phenylated polyalkyl aromatic compounds are shown to be in the scope of the demonstrated reaction (Table). The proposed mechanism suggests that the unsaturation in another part of the molecule (propargyl-group equivalent) is transferred into the cyclohexane ring to yield a benzene

  烷基苯是在基本条件下通过单锅，无过渡金属的偶联方法首次从脂肪烃中合成的。该方法包括两个步骤：将2-溴丙-2-烯基或2-炔丙基环己酮与醇，胺或氨基醇缩合，然后进行碱处理（方案1）。酚类醚和N-苯基化聚烷基芳族化合物显示在已证实的反应范围内（表）。提出的机理表明分子另一部分的不饱和度（炔丙基等价基团）通过一系列质变位移转移到环己烷环中生成苯环。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• DNA-PK INHIBITORS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20180193341A1

  公开（公告）日：2018-07-12

  The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及一种作为DNA-PK抑制剂有用的化合物。本发明还提供了包含上述化合物的药学上可接受的组合物，并且提供了使用这些组合物治疗各种疾病、病症或障碍的方法。